non-alcoholic fatty liver disease


Also found in: Wikipedia.

non-alcoholic fatty liver disease

A fatty liver lacking histologic features typically associated with alcohol abuse, which primarily affects overweight women. With time, patients develop portal changes such as interface hepatitis, increased portal inflammation and fibrosis, and autoantibodies.
 
Risk factors
Diabetes, obesity, hypertension, gallstones, hyperlipidaemia, hypertriglyceridaemia.

Pathogenesis
Uncertain; possibly oxidative stress and lack of antioxidants.

Non-alcoholic fatty liver disease types
• Steatosis;
• Steatosis with inflammation;
• Non-alcoholic steatohepatitis (NASH);
• Cirrhosis.
Mentioned in ?
References in periodicals archive ?
BASF Corporation is introducing Hepaxa, a product that can help tens of millions of patients manage Non-Alcoholic Fatty Liver Disease (NAFLD), one of the most common forms of chronic liver disease.
Germany : BASF launches Hepaxa as first dedicated product in the U.S. to help patients manage Non-Alcoholic Fatty Liver Disease
ARRIVE, a Phase IIa, investigator initiated clinical trial conducted at the University of California San Diego was a randomised, double-blinded, placebo-controlled, 12 weeks, proof-of-concept study that evaluated the safety and efficacy of Aramchol at 600mg/day versus placebo in 50 patients with HIV-associated lipodystrophy and non-alcoholic fatty liver disease, or NAFLD.
Galmed Safety and Efficacy Study of of Aramchol for Treatment of NASH Fails to Meet Primary Endpoint
An article published in 2010 in The New England Journal of Medicine indicated that people with non-alcoholic fatty liver disease are more likely than those without it to have build-ups of cholesterol-filled plaque in their arteries, the blood vessels that supply the heart.
Sugar: Just as bad as alcohol for liver
ARRIVE, a Phase IIa, investigator initiated clinical trial conducted at the University of California San Diego by Professor Rohit Loomba was a randomized, double-blinded, placebo-controlled, 12 weeks, proof-of-concept study that evaluated the safety and efficacy of Aramchol at 600mg/day versus placebo in 50 patients with HIV-associated lipodystrophy and non-alcoholic fatty liver disease, or NAFLD.
Galmed announces ARRIVE Trial did not meet primary endpoint
The findings are significant, researchers said, because liver problems such as non-alcoholic fatty liver disease are surging in the US, affecting 10-35 percent of adults and an increasing number of children.
Liver recovers faster on low-sugar diets
Meta-analysis: vitamin D and non-alcoholic fatty liver disease.
Effect of Resveratrol on Fatty Acid Compositions and Lipophilic Vitamins of Fructose Induced Nonalcoholic Fatty Liver
Keywords: Lipid profile, Non-alcoholic fatty liver disease (NAFLD), NonHDL cholesterol, Ultrasonography.
COMPARISON OF SERUM LIPID PROFILE IN NON ALCOHOLIC FATTY LIVER DISEASE
Coffee drinkers also have a 29% lower risk of non-alcoholic fatty liver disease, a 27% lower risk of liver fibrosis and a 39% lower risk of liver cirrhosis.
Coffee is good for you
According to a previous study, a diet high in animal protein is associated with a higher risk of non-alcoholic fatty liver disease, a condition in which fat builds up in the liver, in overweight people.
Soy, nuts, pulses reduce cholesterol makers; prevent heart disease, stroke
5] It is well established that patients of OSAS exhibit various metabolic abnormalities like insulin resistance, systemic hypertension, dyslipidemia, obesity and oxidative stress including non-alcoholic fatty liver disease (NAFLD).
Liver enzymes in obstructive sleep apnoea syndrome
According to Dr Adi Mor, ChemomAb CEO, the current funding round will enable the company to move forward with its clinical programme for monoclonal antibody, while examining its efficacy and safety profile in patients with non-alcoholic fatty liver disease (NASH) as well as support its continued development for additional fibrotic orphan indications and test its effectiveness in these diseases.
ChemomAb announces USD10m from Series B funding agreement
Their aim is to develop better ways for testing people who could be severely affected by non-alcoholic fatty liver disease (NAFLD) - a condition caused by a build-up of fat in the liver.
University launch project to tackle fatty liver disease

Medical browser ?
Full browser ?